All In Biotech

Drug Trial Radar · NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

680

Planned (sponsor's estimate)

Start

Sep 29, 2025

Primary completion

Mar 10, 2028

Study completion Mar 10, 2032

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation. Participants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or the docetaxel treatment group. Participants in the PF-08046054 treatment group will receive an IV infusion (injected directly into the veins) twice during each 21-day cycle. Participants in the docetaxel treatment group will receive an IV infusion once during each 21-day cycle. Study participation may be up to 5 years if the participant's NSCLC is responding to treatment. The study team will see how each participant is doing with the study treatment during regular visits at the clinic.

Conditions

  • Non-small Cell Carcinoma
  • Non-Small Cell Lung Cancer Metastatic
  • Non-Small Cell Lung Carcinoma

Interventions

  • PF-08046054Drug

    Antibody Drug Conjugate Participants will receive PF-08046054, administered as an IV infusion.

  • Docetaxel monotherapyDrug

    Participants will receive Docetaxel, administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Approximately 5 years

Locations

469 sites in 29 countries. Site status is shown where the registry gives one.

  • Alabama Oncology, Shelby

    Alabaster, Alabama · Recruiting

  • Alabama Oncology, Bessemer

    Bessemer, Alabama · Recruiting

  • Alabama Oncology, St Vincent's Birmingham

    Birmingham, Alabama · Recruiting

  • Alabama Oncology, Brookwood

    Birmingham, Alabama · Recruiting

  • Alabama Oncology, Princeton

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Alabama Oncology, St Vincent's East

    Birmingham, Alabama · Recruiting

  • Alabama Oncology, Grandview Cancer Center

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham, IDS Pharmacy

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Southern Cancer Center

    Daphne, Alabama · Recruiting

  • Southern Cancer Center, PC

    Foley, Alabama · Recruiting

  • Alaska Oncology and Hematology

    Anchorage, Alaska · Recruiting

  • Highlands Oncology Group, PA

    Fayetteville, Arkansas · Recruiting

  • St. Bernards Medical Center

    Jonesboro, Arkansas · Not yet recruiting

  • St. Bernards Medical Center - Paragould

    Paragould, Arkansas · Not yet recruiting

  • Highlands Oncology Group, PA

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group, PA

    Springdale, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • UCLA Hematology/Oncology - Alhambra

    Alhambra, California · Recruiting

  • UCLA Hematology/Oncology - Atascadero

    Atascadero, California · Recruiting

  • Alta Bates Summit Medical Center Comprehensive Cancer Center

    Berkeley, California · Recruiting

  • UCLA Hematology/Oncology - Burbank

    Burbank, California · Recruiting

  • John Muir Health Clinical Research Center

    Concord, California · Recruiting

  • UC San Diego Medical Center - Encinitas

    Encinitas, California · Recruiting

  • UCLA Hematology/Oncoclogy-Encino

    Encino, California · Recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • Providence St. Jude Medical Center

    Fullerton, California · Recruiting

  • UCLA Hematology/Oncology - Irvine

    Irvine, California · Recruiting

  • UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Pavilion

    La Jolla, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • UCSD Koman Family Outpatient Pavilion

    La Jolla, California · Recruiting

  • UCLA Hematology/Oncology - Laguna Hills

    Laguna Hills, California · Recruiting

  • Ronald Reagan UCLA Medical Center, Drug Information Center, Department of Pharmaceutical Services

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology - Marina del Rey

    Marina del Rey, California · Recruiting

  • Providence Medical Foundation

    Orange, California · Not yet recruiting

  • The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange

    Orange, California · Not yet recruiting

  • UCLA Hematology/Oncology - Pasadena

    Pasadena, California · Recruiting

  • UCLA Hematology/Oncology - Porter Ranch

    Porter Ranch, California · Recruiting

  • Roseville Medical Plaza Care Center

    Roseville, California · Recruiting

Showing 40 of 469 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.